<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2410">
  <stage>Registered</stage>
  <submitdate>23/06/2009</submitdate>
  <approvaldate>23/06/2009</approvaldate>
  <nctid>NCT00928629</nctid>
  <trial_identification>
    <studytitle>Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease</studytitle>
    <scientifictitle>Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease. A Cross-sectional Multi-centre Clinical Study in Subjects With Cardiovascular Disease Risk Factors.</scientifictitle>
    <utrn />
    <trialacronym>ACHILLES</trialacronym>
    <secondaryid>D3560L00089</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Arterial Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - Ankle-brachial index (ABI) Screening Test

Other: All Subjects - ABI Screening Test Population: Subjects of either sex, any race, with at least two of the specified CVD risk factors, with no overt cardiovascular disease.


Treatment: surgery: Ankle-brachial index (ABI) Screening Test
Patients will undergo an ABI measurement

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Prevalence of lower extremity peripheral arterial disease, defined as an ankle-brachial index of &lt; or = 0.9 in subjects with at least two of the specified CVD risk factors, with no overt cardiovascular disease</outcome>
      <timepoint>1 visit</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Prevalence of cardiovascular risk factors in the target population</outcome>
      <timepoint>1 visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular risk level and cardiovascular risk factor management in the target population pre and post study</outcome>
      <timepoint>1 visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject characteristics that are determinants of PAD diagnosis</outcome>
      <timepoint>1 visit</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males aged 45 years or above or females aged 55 years or above (age related CVD risk
             factor).

          -  At least two other risk factors for CVD: cigarette smoking, diabetes mellitus,
             hypertension, low HDL or high LDL cholesterol, strong family history of coronary heart
             disease, elevated waist circumference, Aboriginal and/or Torres Strait Islander.

          -  Willingness to participate in study and sufficient command of the English language to
             read and complete study questionnaire.</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Less than 2 risk factors for CVD (other than age), symptoms of PAD, coronary heart
             disease or coronary heart disease risk equivalents

          -  No lipid data collected in the last 12 months

          -  Serious or unstable medical or psychological conditions that, in the opinion of the
             Investigator, would compromise safety or successful participation in the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Screening</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>Research Site - Edgecliff</hospital>
    <hospital>Research Site - Hinchinbrook</hospital>
    <hospital>Research Site - Kingsford</hospital>
    <hospital>Research Site - Kingswood</hospital>
    <hospital>Research Site - Liverpool</hospital>
    <hospital>Research Site - Mosman</hospital>
    <hospital>Research Site - Neutral Bay</hospital>
    <hospital>Research Site - Sydney</hospital>
    <hospital>Research Site - Aspley</hospital>
    <hospital>Research Site - Morayfield</hospital>
    <hospital>Research Site - Parkwood</hospital>
    <hospital>Research Site - Beulah Park</hospital>
    <hospital>Research Site - Glenelg East</hospital>
    <hospital>Research Site - Surrey Downs</hospital>
    <hospital>Research Site - Bridgewater</hospital>
    <hospital>Research Site - Kingston</hospital>
    <hospital>Research Site - Sandy Bay</hospital>
    <hospital>Research Site - Brighton</hospital>
    <hospital>Research Site - Lalor</hospital>
    <hospital>Research Site - Preston</hospital>
    <hospital>Research Site - Booragoon</hospital>
    <hospital>Research Site - East Victoria Park</hospital>
    <hospital>Research Site - Woodvale</hospital>
    <postcode> - Edgecliff</postcode>
    <postcode> - Hinchinbrook</postcode>
    <postcode> - Kingsford</postcode>
    <postcode> - Kingswood</postcode>
    <postcode> - Liverpool</postcode>
    <postcode> - Mosman</postcode>
    <postcode> - Neutral Bay</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Aspley</postcode>
    <postcode> - Morayfield</postcode>
    <postcode> - Parkwood</postcode>
    <postcode> - Beulah Park</postcode>
    <postcode> - Glenelg East</postcode>
    <postcode> - Surrey Downs</postcode>
    <postcode> - Bridgewater</postcode>
    <postcode> - Kingston</postcode>
    <postcode> - Sandy Bay</postcode>
    <postcode> - Brighton</postcode>
    <postcode> - Lalor</postcode>
    <postcode> - Preston</postcode>
    <postcode> - Booragoon</postcode>
    <postcode> - East Victoria Park</postcode>
    <postcode> - Woodvale</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Pretium Pty Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of the study is to establish the prevalence of lower extremity
      peripheral arterial disease (PAD), defined as an ankle-brachial index of less than or equal
      to 0.9, in subjects with at least two of the specified cardiovascular disease (CVD) risk
      factors, with no overt cardiovascular disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00928629</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Simon Fisher</name>
      <address>AstraZeneca</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>